Genetic progression of malignant melanoma

Cancer and Metastasis Reviews

Volumn 35, Issue 1, 2016, Pages 93-107

  Timar J ^a   Vizkeleti, L ^b   Doma, V ^a   Barbai, T ^a   Raso E ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Genomics; Immunotherapy; Melanoma; Metastasis; Target therapy

Indexed keywords

B RAF KINASE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; BRAF PROTEIN, HUMAN; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; MET PROTEIN, HUMAN; MITF PROTEIN, HUMAN; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N-METHYL D-ASPARTATE RECEPTOR SUBTYPE 2A; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PTEN PROTEIN, HUMAN; SCATTER FACTOR RECEPTOR;

ARTICLE; CANCER IMMUNOTHERAPY; CIRCULATING TUMOR CELL; GENETIC ANALYSIS; GENETIC BACKGROUND; GENETIC HETEROGENEITY; GENOMICS; HUMAN; MELANOMA; ONCOGENE; PRIMARY TUMOR; PRIORITY JOURNAL; SKIN TUMOR; TUMOR GROWTH; CARCINOGENESIS; DRUG RESISTANCE; GENETICS; MUTATION; PATHOLOGY;

CARCINOGENESIS; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-MET; PTEN PHOSPHOHYDROLASE; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84960443188     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-016-9613-5     Document Type: Article

References (89)

1. Balch, C. M., Soong, S.-J., & Thompson, J. F. (2004). The natural history of melanoma and factors predicting outcome. In J. F. Thompson, D. L. Morton, & B. B. R. Kroon (Eds.), Textbook of melanoma (pp. 181–199). London: Taylor & Francis Group.
2. Whiteman, D. C., Pavan, W. J., & Bastian, B. C. (2011). The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell & Melanoma Research, 24(5), 879–897.
3. The Cancer Genome Atlas Network. (2015). Genomic classification of cutaneous melanoma. Cell, 161(7), 1681–1696.
4. Wiesner, T., Murali, R., Fried, I., Cerroni, L., Busam, K., Kutzner, H., & Bastian, B. C. (2012). A distinct subset of atypical Spitz tumors is characterized by BRAF mutation and loss of BAP1 expression. American Journal of Surgical Pathology, 36(6), 818–30.
5. Ismail, I. H., Davidson, R., Gagné, J. P., Xu, Z. Z., Poirier, G. G., & Hendzel, M. J. (2014). Germline mutations in BAP1 impair its function in DNA double-strand break repair. Cancer Research, 74(16), 4282–94.
6. Scheuermann, J. C., Alonso, A. G. D., Oktaba, K., Ly-Hartig, N., McGinty, R. K., Fraterman, S., et al. (2010). Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature, 465(7295), 243–247.
7. Ventii, K. H., Devi, N. S., Friedrich, K. L., Chernova, T. A., Tighiouart, M., Van Meir, E. G., et al. (2008). BRCA1-associated protein-1 is a tumor suppressor that requires deubiquitinating activity and nuclear localization. Cancer Research, 68(17), 6953–6962.
8. Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J. P., et al. (2012). A landscape of driver mutations in melanoma. Cell, 150(2), 251–263.
9. Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., et al. (2012). Melanoma genome sequencing reveals frequent PREX2 mutations. Nature, 485(7399), 502–506.
10. Krauthammer, M., Kong, Y., Bacchiocchi, A., Evans, P., Pornputtapong, N., Wu, C., et al. (2015). Exome sequencing identifies recurrent mutations in NF1 and RASopathy genes in sun-exposed melanomas. Nature Genetics, 47(9), 996–1002.
11. Manca, A., Lissia, A., Cossu, A., Rubino, C., Ascierto, P. A., Stanganelli, I., et al. (2013). Mutations in ERBB4 may have a minor role in melanoma pathogenesis. Jornal of Investigative Dermatology, 133(6), 1685–1687.
12. Guan, J., Gupta, R., & Filipp, F. V. (2015). Cancer systems biology of TCGA SKCM: efficient detection of genomic drivers in melanoma. Scientific Reports, 5, 7857.
13. Lee, J. J., Sholl, L. M., Lindeman, N. I., Granter, S. R., Laga, A. C., Shivdasani, P., et al. (2015). Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naive patient melanomas. Clinical Epigenetics, 7(1), 59.
14. Timar, J., Barbai, T., Győrffy, B., & Rásó, E. (2013). Understanding melanoma progression by gene expression signatures. In U. Pfeffer (Ed.), Cancer genomics: Molecular classification, prognosis and response prediction (pp. 47–79). Dordrecht: Springer.
15. Wei, X., Walia, V., Lin, J. C., Teer, J. K., Prickett, T. D., Gartner, J., et al. (2011). Exome sequencing identifies GRIN2A as frequently mutated in melanoma. Nature Genetics, 43(5), 442–446.
16. Viros, A., Fridlyand, J., Bauer, J., Lasithiotakis, K., Garbe, C., Pinkel, D., et al. (2008). Improving melanoma classification by integrating genetic and morphologic features. PLoS Medicine, 5(6), e120.
17. Harbst, K., Staaf, J., Lauss, M., Karlsson, A., Masback, A., Johansson, I., et al. (2012). Molecular profiling reveals low- and high-grade forms of primary melanoma. Clinical Cancer Research, 18(15), 4026–4036.
18. Hoek, K. S., Schlegel, N. C., Brafford, P., Sucker, A., Ugurel, S., Kumar, R., et al. (2006). Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Research, 19(4), 290–302.
19. Allison, K. H., & Sledge, G. W. (2014). Heterogeneity and cancer. [Review]. Oncology (Williston Park), 28(9), 772–778.
20. Jamal-Hanjani, M., Quezada, S. A., Larkin, J., & Swanton, C. (2015). Translational implications of tumor heterogeneity. Clinical Cancer Research, 21(6), 1258–1266.
21. Wang, E., Voiculescu, S., Le Poole, I. C., El-Gamil, M., Li, X., Sabatino, M., et al. (2006). Clonal persistence and evolution during a decade of recurrent melanoma. The Journal of Investigative Dermatology, 126(6), 1372–1377.
22. Chiappetta, C., Proietti, I., Soccodato, V., Puggioni, C., Zaralli, R., Pacini, L., et al. (2015). BRAF and NRAS mutations are heterogeneous and not mutually exclusive in nodular melanoma. Applied Immunohistochemistry & Molecular Morphology, 23(3), 172–177.
23. Lamy, P. J., Castan, F., Lozano, N., Montelion, C., Audran, P., Bibeau, F., et al. (2015). Next-generation genotyping by digital PCR to detect and quantify the BRAF V600E mutation in melanoma biopsies. The Journal of Molecular Diagnostics, 17(4), 366–373.
24. Ding, L., Kim, M. J., Kanchi, K. L., Dees, N. D., Lu, C., Griffith, M., et al. (2014). Clonal architectures and driver mutations in metastatic melanomas. PLoS One, 9(11).
25. Menzies, A. M., Lum, T., Wilmott, J. S., Hyman, J., Kefford, R. F., Thompson, J. F., et al. (2014). Intrapatient homogeneity of BRAFV600E expression in melanoma. The American Journal of Surgical Pathology, 38(3), 377–382.
26. Riveiro-Falkenbach, E., Villanueva, C. A., Garrido, M. C., Ruano, Y., Garcia-Martin, R. M., Godoy, E., et al. (2015). Intra- and inter-tumoral homogeneity of BRAF mutations in melanoma tumors. The Journal of Investigative Dermatology. doi:10.1038/jid.2015.229.
27. Orgaz, J. L., & Sanz-Moreno, V. (2013). Emerging molecular targets in melanoma invasion and metastasis. Pigment Cell & Melanoma Research, 26(1), 39–57.
28. Barbai, T., Fejős, Z., Puskas, L. G., Tímár, J., & Rásó, E. (2015). The importance of the microenvironment: the role of CCL8 in metastasis formation of melanoma. Oncotarget, 6, 29111–29128.
29. Dome, B., Paku, S., Somlai, B., & Timar, J. (2002). Vascularization of cutaneous melanoma involves vessel co-option and has clinical significance. Journal of Pathology, 197(3), 355–362.
30. Christianson, D. R., Dobroff, A. S., Proneth, B., Zurita, A. J., Salameh, A., Dondossola, E., et al. (2015). Ligand-directed targeting of lymphatic vessels uncovers mechanistic insights in melanoma metastasis. Proceedings of the National Academy of Sciences of the United States of America, 112(8), 2521–2526.
31. Leong, S. P., Mihm, M. C., Jr., Murphy, G. F., Hoon, D. S., Kashani-Sabet, M., Agarwala, S. S., et al. (2012). Progression of cutaneous melanoma: implications for treatment. Clinical & Experimental Metastasis, 29(7), 775–796.
32. Pasquali, S., & Spillane, A. (2014). Contemporary controversies and perspectives in the staging and treatment of patients with lymph node metastasis from melanoma, especially with regards positive sentinel lymph node biopsy. [Review]. Cancer Treatment Reviews, 40(8), 893–899.
33. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003). Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma. Nature Reviews Cancer, 3(6), 411–421.
34. Trikha, M., Timar, J., Zacharek, A., Nemeth, J. A., Cai, Y. L., Dome, B., et al. (2002). Role for beta 3 integrins in human melanoma growth and survival. International Journal of Cancer, 101(2), 156–167.
35. Timar, J., Raso, E., Dome, B., Ladanyi, A., Banfalvi, T., Gilde, K., et al. (2002). Expression and function of the AMF receptor by human melanoma in experimental and clinical systems. Clinical & Experimental Metastasis, 19(3), 225–232.
36. Moro, N., Mauch, C., & Zigrino, P. (2014). Metalloproteinases in melanoma. European Journal of Cell Biology, 93(1–2), 23–29.
37. Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews, 33(1), 231–269.
38. Tellez, C., McCarty, M., Ruiz, M., & Bar-Eli, M. (2003). Loss of activator protein-2alpha results in overexpression of protease-activated receptor-1 and correlates with the malignant phenotype of human melanoma. The Journal of Biological Chemistry, 278(47), 46632–46642.
39. Raso, E., Dome, B., Somlai, B., Zacharek, A., Hagmann, W., Honn, K. V., et al. (2004). Molecular identification, localization and function of platelet-type 12-lipoxygenase in human melanoma progression, under experimental and clinical conditions. Melanoma Research, 14(4), 245–250.
40. Timar, J., Tovari, J., Raso, E., Meszaros, L., Bereczky, B., & Lapis, K. (2005). Platelet-mimicry of cancer cells: epiphenomenon with clinical significance. Oncology, 69(3), 185–201.
41. Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., et al. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. The New England Journal of Medicine, 370(7), 599–609.
42. Hendrix, M. J. C., Seftor, E. A., Hess, A. R., & Seftor, R. E. B. (2003). Molecular plasticity of human melanoma cells. Oncogene, 22(20), 3070–3075.
43. Zabierowski, S. E., & Herlyn, M. (2008). Melanoma stem cells: the dark seed of melanoma. [Review]. Journal of Clinical Oncology, 26(17), 2890–2894.
44. Murphy, G. F., Wilson, B. J., Girouard, S. D., Fraqnk, N. Y., & Frank, M. H. (2014). Stem cells and target approaches to melanoma cure. Molecular Aspects of Medicine, 39, 33–49.
45. Bramer, R. R., Watson, I. R., Wu, C.-J., Mobley, A. K., Kamiya, T., Shoshan, E., et al. (2013). Why is melanoma so metastatic? Pigment Cell & Melanoma Research, 27, 19–36.
46. Shakhova, O. (2014). Neural crest stem cells in melanoma development. Current Opinion in Oncology, 26, 215–221.
47. Döme, B., Somlai, B., Ladányi, A., Fazekas, K., Zöller, M., & Tímár, J. (2001). Expression of CD44v3 splice variant is associated with the visceral metastatic phenotype of human melanoma. Virchows Archiv, 439, 628–635.
48. Raso-Barnett, L., Banky, B., Barbai, T., Becsagh, P., Timar, J., & Raso, E. (2013). Demonstration of a melanoma-specific CD44 alternative splicing pattern that remains qualitatively stable, but shows quantitative changes during tumour progression. Plos One, 8, e53883.
49. Döme, B., Somlai, B., & Tímár, J. (2000). The loss of NM23 protein in malignant melanoma predicts lymphatic spread without affecting survival. Anticancer Research, 20, 3971–3974.
50. Lee, J. H., Miele, M. E., Hicks, D. J., Phillips, K. K., Trent, J. M., Weissman, B. E., et al. (1996). KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. Journal of the National Cancer Institute, 88(23), 1731–1737.
51. Kim, M., Gans, J. D., Nogueira, C., Wang, A., Paik, J. H., Feng, B., et al. (2006). Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell, 125(7), 1269–1281.
52. Cirenajwis, H., Ekedahl, H., Lauss, M., Harbst, K., Carneiro, A., Enoksson, J., et al. (2015). Molecular stratification of metastatic melanoma using gene expression profiling: prediction of survival outcome and benefit from molecular targeted therapy. Oncotarget, 6(14), 12297–12309.
53. Verfaillie, A., Imrichova, H., Atak, Z. K., Dewaele, M., Rambow, F., Hulselmans, G., et al. (2015). Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state. Nature Communications, 6, 6683. doi:10.1038/Ncomms7683.
54. Park, J. Y., Amankwah, E. K., Anic, G. M., Lin, H. Y., Walls, B., Park, H., et al. (2013). Gene variants in angiogenesis and lymphangiogenesis and cutaneous melanoma progression. Cancer Epidemiology, Biomarkers & Prevention, 22(5), 827–834.
55. Carlino, M. S., Haydu, L. E., Kakavand, H., Menzies, A. M., Hamilton, A. L., Yu, B., et al. (2014). Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma. British Journal of Cancer, 111(2), 292–299.
56. Pracht, M., Mogha, A., Lespagnol, A., Fautrel, A., Mouchet, N., Le Gall, F., et al. (2015). Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. Journal of the European Academy of Dermatology and Venereology, 29(8), 1530–1538.
57. Thomas, N. E., Edmiston, S. N., Alexander, A., Groben, P. A., Parrish, E., Kricker, A., et al. (2015). Association between and mutational status and melanoma-specific survival among patients with higher risk primary melanoma. JAMA Oncology, 1(3), 359–368.
58. Chiu, C. G., Nakamura, Y., Chong, K. K., Huang, S. K., Kawas, N. P., Triche, T., et al. (2014). Genome-wide characterization of circulating tumor cells identifies novel prognostic genomic alterations in systemic melanoma metastasis. Clinical Chemistry, 60(6), 873–885.
59. Colombino, M., Lissia, A., Capone, M., De Giorgi, V., Massi, D., Stanganelli, I., et al. (2013). Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. Journal of Translational Medicine, 11, 202.
60. Colombino, M., Capone, M., Lissia, A., Cossu, A., Rubino, C., De Giorgi, V., et al. (2012). BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. Journal of Clinical Oncology, 30(20), 2522–2529.
61. Shinozaki, M., Fujimoto, A., Morton, D. L., & Hoon, D. S. (2004). Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clinical Cancer Research, 10(5), 1753–1757.
62. Saroufim, M., Habib, R. H., Gerges, R., Saab, J., Loya, A., Amr, S. S., et al. (2014). Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy. Experimental and Molecular Pathology, 97(3), 315–320.
63. Bradish, J. R., Richey, J. D., Post, K. M., Meehan, K., Sen, J. D., Malek, A. J., et al. (2015). Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy. Modern Pathology, 28(4), 480–486.
64. Yancovitz, M., Litterman, A., Yoon, J., Ng, E., Shapiro, R. L., Berman, R. S., et al. (2012). Intra- and inter-tumor heterogeneity of BRAF(V600E)mutations in primary and metastatic melanoma. PLoS One, 7(1), e29336.
65. Heinzerling, L., Baiter, M., Kuhnapfel, S., Schuler, G., Keikavoussi, P., Agaimy, A., et al. (2013). Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations. British Journal of Cancer, 109(11), 2833–2841.
66. Boursault, L., Haddad, V., Vergier, B., Cappellen, D., Verdon, S., Bellocq, J. P., et al. (2013). Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing. PLoS One, 8(8), e70826.
67. Eriksson, H., Zebary, A., Vassilaki, I., Omholt, K., Ghaderi, M., & Hansson, J. (2015). BRAFV600E protein expression in primary cutaneous malignant melanomas and paired metastases. JAMA Dermatology, 151(4), 410–416.
68. Nardin, C., Puzenat, E., Pretet, J. L., Algros, M. P., Doussot, A., Puyraveau, M., et al. (2015). BRAF mutation screening in melanoma: is sentinel lymph node reliable? Melanoma Research, 25(4), 328–334.
69. Anaka, M., Hudson, C., Lo, P. H., Do, H., Caballero, O. L., Davis, I. D., et al. (2013). Intratumoral genetic heterogeneity in metastatic melanoma is accompanied by variation in malignant behaviors. BMC Medical Genomics, 6, 40. doi:10.1186/1755-8794-6-40.
70. Gartner, J. J., Davis, S., Wei, X. M., Lin, J. C., Trivedi, N. S., Teer, J. K., et al. (2012). Comparative exome sequencing of metastatic lesions provides insights into the mutational progression of melanoma. BMC Genomics, 13, 505. doi:10.1186/1471-2164-13-505.
71. Koh, S. S., Wei, J. P. J., Li, X. M., Huang, R. R., Doan, N. B., Scolyer, R. A., et al. (2012). Differential gene expression profiling of primary cutaneous melanoma and sentinel lymph node metastases. Modern Pathology, 25(6), 828–837.
72. Sabatino, M., Zhao, Y., Voiculescu, S., Monaco, A., Robbins, P., Karai, L., et al. (2008). Conservation of genetic alterations in recurrent melanoma supports the melanoma stem cell hypothesis. Cancer Research, 68(1), 122–131.
73. Carlino, M. S., Long, G. V., Kefford, R. F., & Rizos, H. (2015). Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma. [Review]. Critical Reviews in Oncology/Hematology. doi:10.1016/j.critrevonc.2015.08.021.
74. Michielin, O., & Hoeller, C. (2015). Gaining momentum: new options and opportunities for the treatment of advanced melanoma. [Review]. Cancer Treatment Reviews, 41(8), 660–670.
75. Van Allen, E. M., Wagle, N., Sucker, A., Treacy, D. J., Johannessen, C. M., Goetz, E. M., et al. (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1), 94–109.
76. Spagnolo, F., Ghiorzo, P., Orgiano, L., Pastorino, L., Picasso, V., Tornari, E., et al. (2015). BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies. [Review]. Oncology Targets and Therapy, 8, 157–168.
77. Nazarian, R., Shi, H., Wang, Q., Kong, X., Koya, R. C., Lee, H., et al. (2010). Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature, 468(7326), 973–977.
78. Wheler, J., Yelensky, R., Falchook, G., Kim, K. B., Hwu, P., Tsimberidou, A. M., et al. (2015). Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance. BMC Cancer, 15, 61. doi:10.1186/s12885-015-1029-z.
79. Hoogstraat, M., Gadellaa-van Hooijdonk, C. G., Ubink, I., Besselink, N. J., Pieterse, M., Veldhuis, W., et al. (2015). Detailed imaging and genetic analysis reveal a secondary BRAF(L505H) resistance mutation and extensive intrapatient heterogeneity in metastatic BRAF mutant melanoma patients treated with vemurafenib. Pigment Cell & Melanoma Research, 28(3), 318–323.
80. Wagle, N., Emery, C., Berger, M. F., Davis, M. J., Sawyer, A., Pochanard, P., et al. (2011). Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. Journal of Clinical Oncology, 29(22), 3085–3096.
81. Johannessen, C. M., Boehm, J. S., Kim, S. Y., Thomas, S. R., Wardwell, L., Johnson, L. A., et al. (2010). COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature, 468(7326), 968–972.
82. Roesch, A. (2015). Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma. Oncotarget, 34, 2951–2957.
83. Shi, H., Moriceau, G., Kong, X., Koya, R. C., Nazarian, R., Pupo, G. M., et al. (2012). Preexisting MEK1 exon 3 mutations in V600E/KBRAF melanomas do not confer resistance to BRAF inhibitors. Cancer Discovery, 2(5), 414–424.
84. Jönsson, G., Busch, C., Knappskog, S., Geisler, J., Miletic, H., Ringner, M., et al. (2010). Gene expression profiling-based identification of molecular subtypes in stage IV melanomas with different clinical outcome. Clinical Cancer Research, 16(13), 3356–3367.
85. Krepler, C., Certa, U., Wacheck, V., Jansen, B., Wolff, K., & Pehamberger, H. (2004). Pegylated and conventional interferon-alpha induce comparable transcriptional responses and inhibition of tumor growth in a human melanoma SCID mouse xenotransplantation model. Journal of Investigative Dermatology, 123(4), 664–669.
86. Johnson, D. B., Lovly, C. M., Flavin, M., Panageas, K. S., Ayers, G. D., Zhao, Z., et al. (2015). Impact of NRAS mutations for patients with advanced melanoma treated with immune therapies. Cancer Immunology Research, 3(3), 288–295.
87. Shin, D. S., & Ribas, A. (2015). The evolution of checkpoint blockade as a cancer therapy: what’s here, what’s next? Current Opinion in Immunology, 33, 23–35.
88. Snyder, A., Wolchok, J. D., & Chan, T. A. (2015). Genetic basis for clinical response to CTLA-4 blockade. [Comment Letter]. The New England Journal of Medicine, 372(8), 783.
89. Herbst, R. S., Soria, J. C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., et al. (2014). Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature, 515(7528), 563–567.